Literature DB >> 17691920

N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed.

Silvio Caccia1.   

Abstract

In recent years several arylpiperazine derivatives have reached the stage of clinical application, mainly for the treatment of depression, psychosis or anxiety. Examples are the pyrimidinylpiperazine buspirone, the chlorophenylpiperazine derivatives nefazodone and trazodone, the dichlorophenylpiperazine aripiprazole and the benzisothiazolyl derivatives perospirone and ziprasidone. Most of them undergo extensive pre-systemic and systemic metabolism including CYP3A4-dependent N-dealkylation to 1-aryl-piperazines. These metabolites are best known for the variety of serotonin receptor-related effects they cause in man and animals, although some have affinity for other neurotransmitter receptors; others, however, are still largely unexplored despite uncontrolled use as amphetamine-like designer drugs. Once formed they distribute extensively in tissues, including brain which is the target site of most arylpiperazine derivatives, and are then primarily biotransformed by CYP2D6-dependent oxidation to hydroxylates which are excreted as conjugates; only 1-(2-benzisothiazolyl)-piperazine is more susceptible to sulfur oxidation than to aromatic hydroxylation. In studies analysing animal brain and human blood, 1-aryl-piperazine concentrations were either higher or lower than the parent compound(s), although information is available only for some derivatives. At steady state, the metabolite-to-parent drug ratios varied widely among individuals taking the same dosage of the same arylpiperazine derivative. This is consistent with the known individual variability in the expression and activity of CYP3A4 and CYP2D6. This review also surveys current published information on physiological and pathological factors affecting the 1-aryl-piperazine-to-parent drug ratios and examines the potential role of 1-aryl-piperazine formation in the pharmacological actions of the arylpiperazine derivatives that are already or will shortly be available in major markets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17691920     DOI: 10.2174/138920007781368908

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  11 in total

1.  Design, synthesis, radiolabeling, and in vivo evaluation of carbon-11 labeled N-[2-[4-(3-cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a potential positron emission tomography tracer for the dopamine D(4) receptors.

Authors:  Enza Lacivita; Paola De Giorgio; Irene T Lee; Sean I Rodeheaver; Bryan A Weiss; Claudia Fracasso; Silvio Caccia; Francesco Berardi; Roberto Perrone; Ming-Rong Zhang; Jun Maeda; Makoto Higuchi; Tetsuya Suhara; John A Schetz; Marcello Leopoldo
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

2.  LP-211 is a brain penetrant selective agonist for the serotonin 5-HT(7) receptor.

Authors:  Peter B Hedlund; Marcello Leopoldo; Silvio Caccia; Gor Sarkisyan; Claudia Fracasso; Giuliana Martelli; Enza Lacivita; Francesco Berardi; Roberto Perrone
Journal:  Neurosci Lett       Date:  2010-06-23       Impact factor: 3.046

3.  The Therapeutic Potential of 2-{[4-(2-methoxyphenyl)piperazin-1-yl]alkyl}-1H-benzo[d]imidazoles as Ligands for Alpha1-Adrenergic Receptor - Comparative In Silico and In Vitro Study.

Authors:  Jelena Z Penjišević; Vladimir B Šukalović; Deana B Andrić; Relja Suručić; Sladjana V Kostić-Rajačić
Journal:  Appl Biochem Biotechnol       Date:  2022-05-04       Impact factor: 3.094

Review 4.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

5.  Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2009-07-27       Impact factor: 3.455

Review 6.  Predicting the clinical relevance of drug interactions from pre-approval studies.

Authors:  Silvio Caccia; Silvio Garattini; Luca Pasina; Alessandro Nobili
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters.

Authors:  Enza Lacivita; Paola De Giorgio; Daniela Patarnello; Mauro Niso; Nicola A Colabufo; Francesco Berardi; Roberto Perrone; Grzegorz Satala; Beata Duszynska; Andrzej J Bojarski; Marcello Leopoldo
Journal:  Exp Brain Res       Date:  2013-04-10       Impact factor: 1.972

8.  Prediction of overall in vitro microsomal stability of drug candidates based on molecular modeling and support vector machines. Case study of novel arylpiperazines derivatives.

Authors:  Szymon Ulenberg; Mariusz Belka; Marek Król; Franciszek Herold; Weronika Hewelt-Belka; Agata Kot-Wasik; Tomasz Bączek
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

9.  Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants.

Authors:  Kuo-Hsuan Chang; Chiung-Mei Chen; Chun-Li Wang; Hui-Tzu Tu; Yu-Tung Huang; Hsiu-Chuan Wu; Chien-Hung Chang; Shang-Hung Chang
Journal:  Front Aging Neurosci       Date:  2022-02-04       Impact factor: 5.750

Review 10.  Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics.

Authors:  Francisco José Toja-Camba; Nerea Gesto-Antelo; Olalla Maroñas; Eduardo Echarri Arrieta; Irene Zarra-Ferro; Miguel González-Barcia; Enrique Bandín-Vilar; Victor Mangas Sanjuan; Fernando Facal; Manuel Arrojo Romero; Angel Carracedo; Cristina Mondelo-García; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2021-06-23       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.